Ionis Pharmaceuticals, Inc., a RNA-targeted drug discovery and development company, focuses on developing drugs for patients with severe and rare diseases. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
IONS Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Ionis Pharmaceuticals Inc. To summarize, we found that Ionis Pharmaceuticals Inc ranked in the 29th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. The most interesting components of our discounted cash flow analysis for Ionis Pharmaceuticals Inc ended up being:
The compound growth rate in the free cash flow of Ionis Pharmaceuticals Inc over the past 4.76 years is 0.18%; that's better than 57.81% of cash flow producing equities in the Healthcare sector, where it is classified.
91% of the company's capital comes from equity, which is greater than 79.66% of stocks in our cash flow based forecasting set.
The business' balance sheet reveals debt to be 9% of the company's capital (with equity being the remaining amount). Approximately just 20.3% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Ionis Pharmaceuticals Inc? See DXCM, LCI, ENTA, GTS, and ZBH.
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that William Andrews, MD, FACP, has joined the company as chief medical officer (CMO), effective immediately. Dr. Andrews will lead medical, clinical and regulatory functions in support of the company's two commercial-stage products TEGSEDI® (inotersen) and WAYLIVRA® (volanesorsen) and will also guide development of the multiple clinical-stage therapeutics in the pipeline. Former CMO Louis St. L. O'Dea, MB, BCh, BAO, FRCP(C), will serve as an advisor to the company to ensure a smooth transition.
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Tuesday, July 14th at 10:00 a.m. Eastern Time to review its neurology franchise. The approximately 90-minute webcast will include presentations from Brett P. Monia, Ph.D., chief executive officer; C. Frank Bennett, Ph.D., chief scientific officer and franchise leader for neurology; Holly Kordasiewicz, Ph.D., vice president, neurology research; and Frank Rigo, Ph.D., vice president, functional genomics and drug discovery. The agenda for the webcast will be as follows:
Ionis Pharmaceuticals, Inc. (IONS) BMO 2020 Prescriptions for Success Healthcare Conference June 23, 2020, 02:00 PM ET Company Participants Eric Swayze - SVP of Research Wade Walke - IR Conference Call Participants Do Kim - BMO Capital Markets Presentation Do Kim Good morning. My name is Do Kim. I'm one...
Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious and rare diseases, today announced that Damien McDevitt, chief executive officer, and Kyle Jenne, chief commercial officer, will participate in a fireside chat at the BMO 2020 Prescriptions for Success Healthcare Conference, which is being held virtually, on Tuesday, June 23, 2020 at 3:30 p.m. ET.